Cancer biomarkers have become the foundation of modern oncology, enabling earlier diagnosis, better treatment selection, and improved patient monitoring. As healthcare systems shift toward precision medicine, demand for biomarker-based testing continues to rise across hospitals, diagnostic laboratories, and pharmaceutical companies.
The market is largely shaped by the burden of common cancers and the growing use of molecular diagnostics. Breast cancer remains the largest application area, while genetic biomarkers and diagnostic testing continue to dominate due to their clinical value and widespread adoption.
Cancer Biomarkers Market Share by Segment (2025)
| Segment Category | Leading Segment | Market Share |
|---|---|---|
| By Type | Breast Cancer | 35% |
| By Biomolecule | Genetic Biomarkers | 40% |
| By Application | Diagnostics | 40% |
| By Technology | Imaging Technology | 60% |
Breast Cancer Biomarkers Hold the Largest 35% Market Share
Breast cancer accounts for 35% of the global cancer biomarkers market, making it the largest disease segment. The dominance reflects both the high number of diagnosed patients and the widespread use of biomarker testing throughout the treatment journey.
Breast cancer is now the world’s most frequently diagnosed cancer. According to global public health estimates, around 2.3 million women were diagnosed with breast cancer in 2022, while nearly 670,000 deaths were reported worldwide. Population growth and aging are expected to push annual new cases beyond 3 million by 2040, significantly increasing demand for biomarker testing.
Hormone receptor testing (ER and PR), HER2 testing, BRCA mutation analysis, and multigene assays have become routine in clinical practice. These biomarkers help physicians determine whether patients should receive hormone therapy, targeted drugs, chemotherapy, or immunotherapy, improving treatment precision while reducing unnecessary therapies.
The strong presence of breast cancer screening programs across North America and Europe further supports market growth. Governments continue investing in mammography and molecular testing to improve early detection rates, driving higher utilization of cancer biomarkers.
Prostate cancer contributes 20% of the market. Aging populations and increasing PSA testing continue supporting demand, particularly across developed economies.
Colorectal cancer represents 15%, driven by growing screening programs and rising disease incidence associated with lifestyle factors.
Cervical cancer and liver cancer each account for 10%, while lung cancer contributes 5%, reflecting comparatively lower biomarker testing volumes despite high mortality rates.
Genetic Biomarkers Lead Precision Oncology with 40% Market Share
Among biomolecules, genetic biomarkers account for 40% of the market, making them the most widely adopted category.
Cancer treatment has shifted from identifying where tumors originate to understanding the genetic mutations driving disease progression. Testing for mutations such as EGFR, KRAS, BRAF, BRCA1, BRCA2, ALK, ROS1, and PIK3CA allows clinicians to match patients with highly targeted therapies.
Advances in next-generation sequencing (NGS) have made comprehensive genomic profiling faster and more affordable. Large-scale genome initiatives and precision medicine programs have accelerated the adoption of genetic biomarker testing across oncology centers.
Epigenetic biomarkers hold 25% of the market and are expanding rapidly as researchers explore DNA methylation and histone modifications for early cancer detection. Several epigenetic therapies have already received regulatory approval, encouraging further investment.
Proteomic biomarkers contribute 15%, supporting protein-based diagnostics and therapeutic monitoring. Metabolic biomarkers account for 10%, while emerging biomarker classes collectively represent another 10%.
Major industry participants including Roche, Thermo Fisher Scientific, Illumina, QIAGEN, Agilent Technologies, and Bio-Rad Laboratories continue expanding genomic testing portfolios through new assay launches and companion diagnostic partnerships.
Diagnostics Continue to Drive 40% of Market Demand
Diagnostics remain the largest application segment, representing 40% of total market revenue.
Cancer biomarkers are increasingly used throughout the patient journey—from identifying cancer risk and confirming diagnosis to monitoring treatment response and detecting disease recurrence. Hospitals and laboratories are integrating molecular testing into routine oncology workflows because earlier diagnosis significantly improves treatment outcomes.
Drug discovery and development account for 25% of the market as pharmaceutical companies rely on biomarkers to identify suitable patient populations during clinical trials. Personalized medicine also contributes 25%, reflecting the industry’s move toward individualized treatment strategies based on tumor biology rather than cancer location alone.
The remaining 10% includes disease monitoring, recurrence surveillance, and research applications.
Imaging Technologies Dominate with 60% Market Share
By technology, imaging technologies command 60% of the cancer biomarkers market.
Imaging biomarkers offer non-invasive methods to detect tumors, monitor disease progression, evaluate treatment response, and identify recurrence. PET, CT, MRI, and molecular imaging continue to play a central role alongside laboratory-based biomarker testing.
Their ability to repeatedly assess tumors without invasive procedures makes imaging biomarkers highly valuable in oncology care.
OMICS technologies account for the remaining 40% and are experiencing strong growth. High-throughput genomics, transcriptomics, proteomics, and metabolomics enable researchers to analyze thousands of biological molecules simultaneously, accelerating biomarker discovery and advancing precision oncology.
As sequencing costs continue declining and artificial intelligence enhances data interpretation, OMICS platforms are expected to gain a larger share of future cancer biomarker research and clinical applications.
Checkout the Market Report Now at: https://www.towardshealthcare.com/checkout/5335
Industry Investment Continues to Expand Biomarker Innovation
Leading healthcare companies continue investing heavily in cancer biomarker technologies.
Thermo Fisher Scientific generated approximately US$43 billion in annual revenue, while Roche Group reported revenues exceeding CHF 60 billion, with diagnostics remaining a major business segment. Illumina continues to strengthen its leadership in next-generation sequencing platforms used extensively in cancer biomarker discovery, and QIAGEN has expanded its companion diagnostics portfolio through collaborations with pharmaceutical companies developing targeted cancer therapies.
Growing government support for precision medicine, expanding cancer screening initiatives, increasing genomic testing, and continued pharmaceutical investment are expected to keep breast cancer biomarkers, genetic biomarkers, diagnostic applications, and imaging technologies at the center of the global cancer biomarkers market over the coming decade.
Get Easy Access
Access our exclusive, data-rich dashboard dedicated to the diagnostics market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting delivers strategic insights across the cancer diagnostics market, including liquid biopsy, molecular diagnostics, imaging diagnostics, genetic testing, biomarker testing, and companion diagnostics. We support healthcare companies and diagnostic innovators with market intelligence and data-driven strategies to accelerate early detection, precision medicine, and oncology advancements.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium